Abstract. Hyperhomocysteinemia (HHcy) is a risk factor for cardiovascular disease. The S-nitrosylation of proteins is involved in the regulation of cardiovascular functions. However, whether homocysteine (Hcy) impairs vascular functions through the inhibition of protein S-nitrosylation in the endothelium remains to be determined. The experiments were performed in human umbilical vein endothelial cells (HUVECs). Male Sprague-Dawley rats, with or without administration of L-methionine, were used for the in vivo validation of findings. S-nitrosylation was analyzed using immunofluorescence for nitrosocysteine, and further confirmed by the biotin switch method. The levels of reactive oxygen species (ROS) were detected by 2',7'-dichlorofluorescein diacetate (DCFH-DA) staining. The levels of nitric oxide (ΝΟ) were determined by the nitrate reduction method. Protein expression was analysed by western blot analysis. The activity of nuclear factor κB (NF-κB) was evaluated by an electrophoretic mobility shift assay (EMSA). The levels of plasma Hcy were measured by ELISA. The results showed that Hcy significantly reduced the levels of protein S-nitrosylation in HUVECs and endothelial S-nitrosylation of aorta. This reduction of protein S-nitrosylation was accompanied by increasing ROS, decreasing phosphorylation levels of Akt and endothelial nitric oxide synthase (eNOS), and reduced levels of nitric oxide in HUVECs. In addition, it was found that Hcy increased the protein expression of vascular cell adhesion molecule-1 by attenuating the cytoplasm S-nitrosylation of NF-κB (p65).
Introduction
S-nitrosylation is a protein modification in which a nitrosyl group covalently attaches to the thiol group on protein cysteine residues, forming an S-nitrosothiol. S-nitrosylation is a redox mechanism for the dynamic and post-translational regulation of most or all of the major classes of proteins and is independent of enzyme catalysis, labile modification, and on/off switch-like photophosphorylation, involved in cellular signal transduction (1) (2) (3) . The S-nitrosylation of proteins is involved in the regulation of cardiovascular functions (2) . Classically, nitric oxide (NO) is generated through the activation of endothelial ΝΟ synthase (eNOS), and NO diffuses from the endothelial cells to the vascular smooth muscle cells, where it binds to its intracellular receptor, soluble guanylyl cyclase, and activates protein kinase G to mediate vasorelaxation (1) (2) (3) . However, NO also regulates widespread and diverse biologic functions in the endothelium, such as ion channel activity (4), antioxidative stress (5), anti-apoptotic mechanisms (6) ; and anti-inflammatory responses (3, 7) . These functions have been attributed to the protein S-nitrosylation (3) (4) (5) (6) (7) . It has been shown that many factors are involved in the regulation of protein S-nitrosylation in endothelial cells. Tumor necrosis factor-α (8), oxidized low-density lipoprotein (8) ; and high glucose (9) decrease protein S-nitrosylation, whereas shear stress (10), 17b-estradiol (3); and acute hypoxia (11) upregulate protein S-nitrosylation in endothelial cells.
Homocysteine (Hcy) is a sulfur-containing amino acid formed during the transmethylation of methionine. High plasma levels of Hcy, termed hyperhomocysteinemia (HHcy), is an independent risk factor for cardiovascular disease. Elevated plasma levels of Hcy are found in 5-10% of the general population and in up to 40% of patients with vascular disease (12) . It has been reported that Hcy reduced the levels of NO (13) . However, whether Hcy also impairs protein Reactive oxygen species (ROS) assay. Intracellular ROS generation was assessed using 2' ,7'-dichlorofluorescein diacetate (DCFH-DA). ROS in the cells oxidize DCFH-DA, yielding the fluorescent compound 2' ,7'-dichlorofluorescein (DCF). The levels of ROS were detected using the ROS assay kit (Beyotime Institute of Biotechnology, Nantong, China).
Homocysteine reduces protein S-nitrosylation in endothelium
Nitrate/nitrite assay. The levels of NO of the conditioned medium were determined by estimating the total concentration of nitrate/nitrite using a nitrate/nitrite colorimetric assay kit (Jiancheng Technology Co., Ltd., Nanjing, China).
Plasma Hcy assay. The rats were anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg) (14) . The blood was collected in centrifuge tubes (containing EDTA) from the aortas of fasted rats. The blood was immediately cooled on ice and centrifuged at 3,000 x g for 20 min at 4̊C. Plasma was then stored at -20̊C until assayed. Total plasma Hcy concentrations were measured using an ELISA kit (R&D Systems, Inc., Minneapolis, MN, USA).
Immunofluorescence. The HUVECs were fixed with 4% paraformaldehyde for 15 min at room temperature. The cells were permeabilized with 0.1% (v/v) Triton X-100 for 15 min, and blocked with 5% horse serum for 30 min, and incubated with anti-nitrosocysteine rabbit polyclonal antibody (Abcam, Cambridge, MA, USA) or anti-p65 antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at 4̊C. After overnight incubation the cells were treated with a FITC-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology, Inc.) for 30 min at room temperature. Nuclei were stained with 4,6-diamidino-phenylindole (DAPI; 0.2 mg/ml in 10 mM Tris-HCl, pH 7.0, 10 mM EDTA, 100 mM NaCl). To validate the anti-S-nitrosocysteine antibody, we treated HUVECs for 10 min with 1 mM DL-dithiothreitol (DTT), which caused severe loss of S-nitrosocysteine staining. For the negative control, fixed and permeabilized cells were preincubated with 0.8% HgCl 2 for 1 h at 37̊C (8) .
To stain the aorta, 10-µm sections were placed on glass slides and fixed for 10 min in acetone at room temperature. After permeabilization, the sections were incubated with rabbit polyclonal anti-nitrosocysteine antibody and a mouse monoclonal anti-vWF antibody overnight at 4̊C. The incubation with a TRITC-conjugated goat anti-rabbit IgG (H+L) (Santa Cruz Biotechnology) and a FITC-conjugated goat anti-mouse IgG (H+L) was performed. Nuclei were stained with DAPI. The results were visualized using fluorescence microscopy (Olympus, Tokyo, Japan). The mean fluorescence intensity was analyzed by Image-Pro Plus 6.0 software (Media Cybernetics Inc., Bethesda, MD, USA) (3).
Detection of S-nitrosylated proteins by the biotin switch assay.
The HUVECs were lysed in HEN buffer (100 mM Hepes, 1 mM EDTA, and 0.1 mM neocuproine, pH 8.0) containing 1% (w/v) SDS and 1 mM PMSF plus protease inhibitors (Hoffmann-La Roche, Basel, Switzerland). The proteins extracted from the HUVECs were quantified using a BCA assay kit (Thermo Fisher Scientific/Pierce). Equal amounts of protein were incubated with HEN buffer containing 2.5% (w/v) SDS and 0.1% (v/v) S-methyl-methanethiosulfonate (Fluka/Sigma-Aldrich) at 50̊C in the dark for 20 min. The extracts were precipitated with cold acetone. The proteins were re-suspended in HEN buffer plus 1% SDS. S-nitrosothiols were decomposed by adding ascorbate followed by incubation with 2.5 mg/ml biotin-HPDP (Thermo Fisher Scientific/Pierce) for 1 h at room temperature. The proteins were subsequently precipitated again using acetone and resuspended in non-reducing Laemmli loading buffer. For purification of the biotinylated proteins, the proteins precipitated by acetone were diluted with neutralization buffer [20 mM HEPES (pH 7.7, 100 mM NaCl, 1 mM EDTA, and 0.5% (v/v) Triton X-100] and 50% streptavidin agarose suspension (Fluka/Sigma-Aldrich) and incubated for 1 h at room temperature. The proteins were eluted with elution buffer.
Samples from the biotin switch assay were separated on 12% SDS polyacrylamide gels and transferred to PVDF membranes (EMD Millipore, Billerica, MA, USA). PVDF membranes were blocked with 5% non-fat dried milk for 1 h at 37̊C and incubated with specific antibodies, including horseradish peroxidase-conjugated anti-biotin (Cell Signaling Technology, Danvers, MA, USA), anti-β-actin antibody (Abcam), and anti-p65 antibody, overnight at 4̊C. Membranes were then incubated with a horseradish peroxidase-conjugated goat against mouse IgG (H+L), followed by enhanced chemiluminescence using the SuperSignal West Pico Substrate kit (both from Thermo Fisher Scientific/Pierce). The protein bands were detected and analyzed using the Chemi-Doc-it HR 410 imaging system (Ultra-Violet Products, Ltd., Upland, CA, USA) (15) .
Western blot analysis. The cells were lysed on ice for 1 h in RIPA buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Triton X-100 (v/v), 1% deoxycholic acid (w/v), and 0.1% sodium dodecyl sulfate)] containing 0.5 mM PMSF and protease inhibitors (Hoffmann-La Roche). The protein concentration was measured. Each sample was subsequently denatured by boiling for 10 min in Laemmli loading buffer. Equal amounts of protein were separated by 12% SDS-polyacrylamide gel electrophoresis and transferred to PVDF membranes. After blocking with 5% non-fat dried milk for 1 h at 37̊C, the membranes were incubated overnight at 4̊C with the following antibodies: anti-phospho-Akt (Ser-473) antibody, anti-phospho-eNOS (Ser-1177) antibody (Cell Signaling Technology), anti-Akt antibody, anti-eNOS antibody (Abcam), anti-vascular cell adhesion molecule-1 (VCAM-1) antibody (Santa Cruz Biotechnology, Inc.), and anti-β-actin antibody. After washing, the membranes were incubated using horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit IgG (Thermo Fisher Scientific/Pierce) for 1 h at 37̊C, followed by enhanced chemiluminescence using the SuperSignal West Pico Substrate kit. The protein bands were analyzed using the Chemi Doc-it HR 410 imaging system (16) .
Electrophoretic mobility shift assay (EMSA). Nuclear and cytoplasmic protein extraction were investigated. NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific/Pierce) were used to extract the cell proteins according to the manufacturer's instructions. The nuclear proteins were quantified and stored at -80̊C until they were used for the EMSA.
Nuclear factor κB (NF-κB) DNA-binding activity. The EMSA was performed with IRDye 700 infrared dye-labeled double-stranded oligonucleotides containing an NF-κB consensus site (5'-AGT TGA GGG GAC TTT CCC AGG C-3' , 3'-TCA ACT CCC CTG AAA GGG TCC G-5') (LI-COR Biosciences, Lincoln, NE, USA). The nuclear extracts (8 µg per reaction) and 50 fmol of the oligonucleotides were preincubated in 20 µl binding buffer [10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 3 mM DTT, 0.5 µg poly dI-dC, 5 mM MgCl 2 , and 0.1% Tween-20)] for 30 min at room temperature. The specificity of the bands was confirmed by supershifting with specific antibodies of p65 and p50 (Santa Cruz Biotechnology, Inc.) and by competition with 100 x specific cold competitor (100 x SPC) and 100 x non-specific cold competitor (100 x NSC) (LI-COR Biosciences). The DNA protein complexes were separated on 5% native polyacrylamide gels for 60 min at 100 V in 0.5X TBE buffer. The signals were scanned and quantified using the Odyssey infrared imaging system (LI-COR Biosciences) (17) .
Statistical analysis. Data are presented as the means ± SEM. One-way ANOVA followed by an LSD test and Student's t-tests were used for the comparison between the groups. P<0.05 was considered to be statistically significant. The analysis was performed using the SPSS 13.0 software (SPSS Inc., Chicago, IL, USA).
Results

Hcy reduces protein S-nitrosylation in HUVECs.
HUVECs were treated with different doses of Hcy (0.125, 0.5 and 2 mM) for 24 h. Cell morphology was normal following treatment with Hcy (data not shown). The protein S-nitrosylation was detected for S-nitrosocysteine using immunofluorescence and was further confirmed by the biotin switch method. We found that treatment with different doses of Hcy (2, 0.5 and 0.125 mM) resulted in the reductions (44>34>8%, respectively) in the protein S-nitrosylation compared with the control group (Fig. 1A and B) . However, there were no significant differences between 0.125 mM and the control. Protein S-nitrosylation was significantly decreased in HUVECs treated with Hcy (0.5 or 2 mM). In addition, we found that S-nitrosocysteine was present in the nuclei and cytosol of the HUVECs (Fig. 1A) . The biotin switch method on HUVECs further confirmed our finding (Fig. 1C) .
Hyperhomocysteinemia attenuates endothelial S-nitrosylation of aortas in the rat. We assessed whether HHcy promoted a decrease in S-nitrosylation levels in the endothelium. HHcy was induced in rats by feeding a high-methionine diet to male Sprague-Dawley rats. As a result, the high-methionine diet resulted in a significant 3.6-fold increase in the plasma Hcy levels (17.2 vs. 4.8 mM in control rats) (Fig. 2C) . Furthermore, we detected a significant decrease in nitrosocysteine staining in the endothelium of thoracic aorta sections of L-methionine-fed rats compared with the controls ( Fig. 2A and B) .
ROS scavengers reverse the effect of Hcy on protein S-nitrosylation. ROS are involved in the deleterious effects of Hcy on endothelial functions (13). It is unclear whether Hcy reduces protein S-nitrosylation by ROS.
The results showed that Hcy significantly increased ROS levels. This effect was blocked by vitamin C (VitC) and N-acetylcysteine (NAC), which are both ROS scavengers (18) (Fig. 3A and B) . Furthermore, VitC and NAC significantly increased the decreased levels of protein S-nitrosylation reduction by Hcy (Fig. 3C and D) , suggesting that ROS play a crucial role in the Hcy-induced reduction of protein S-nitrosylation in endothelial cells.
Furthermore, the results showed that protein S-nitrosylation levels were partially restored in the Hcy-treated endothelial cells in the presence of the NO donor S-nitrosoglutathione (GSNO). However, these levels of S-nitrosylation were abrogated by DTT ( Fig. 4A and B) . These data suggested that Hcy reduces protein S-nitrosylation by decreasing the levels of NO.
Involvement of oxidative stress and the Akt/eNOS/NO signaling pathway.
We investigated whether the Akt/eNOS/NO pathway is involved in Hcy-induced protein S-nitrosylation in endothelial cells. The protein levels of Akt and eNOS were not affected by Hcy. (19) . Thus, after treatment with Hcy, we determined the phosphorylation of Akt at Ser-473 and eNOS at Ser-1177 and the NO levels of cell-free supernatants in HUVECs. The results showed that Hcy downregulated the phosphorylation of Akt at Ser-473 and eNOS at Ser-1177 and decreased the levels of NO, while the effects were partially reversed by the addition of VitC (Fig. 5A-C) . Furthermore, the restoration of protein S-nitrosylation by VitC was abrogated by the LY294002 (PI3K/Akt inhibitor) and L-NAME (NOS inhibitor; it reversibly inhibits eNOS activity) (Fig. 6A-C) . These results suggested that Hcy increases the levels of intracellular ROS and subsequently decreases NO production by suppressing the Akt/eNOS/NO signaling pathway, which inhibits protein S-nitrosylation in HUVECs.
Hcy upregulates NF-κB activity. To investigate whether Hcy-induced protein S-nitrosylation affects NF-κB activity, we detected the levels of S-nitrosylation and the activity of NF-κB. The results showed that Hcy abrogated NF-κB S-nitrosylation, which was accompanied by an increase in the activity of NF-κB (Fig. 7A-D) .
Hcy effect on levels of S-nitrosylation of p65 and VCAM-1.
To determine the relationship between S-nitrosylated NF-κB (p65) and VCAM-1, our data showed that Hcy increased the protein expression of VCAM-1, whereas GSNO blocked the increase of VCAM-1 protein levels induced by Hcy, and DTT restored the expression of VCAM-1 (Fig. 8) . However, the expression of VCAM-1 is upregulated along with the levels of cytoplasm S-nitrosylated NF-κB (p65) decreasing (Fig. 4A and B) .
Discussion
To the best of our knowledge, the present study has demonstrated for the first time that, Hcy attenuated the protein S-nitrosylation levels in HUVECs and an in vivo model. Attenuation of the S-nitrosylation induced by Hcy was mediated by the ROS/Akt/ eNOS/NO signaling pathway. Hcy induces ROS production, followed by the inhibition of Akt and eNOS phosphorylation. As a result, the reduced intracellular NO leads to the inhibition of protein S-nitrosylation. Moreover, we found that Hcy may upregulate the expression of VCAM-1 via the reduction of cytoplasm S-nitrosylation of NF-κB in endothelial cells. S-nitrosylation is a reversible covalent bonding to the SH group of a reactive cysteine on the target protein (2). Protein S-nitrosylation is also a ubiquitous post-translational modification that is responsible for a broad spectrum of biological functions. In endothelial cells, S-nitrosylation is able to affect cellular metabolic processes and regulate Figure 7 . Effect of homocysteine (Hcy) on S-nitrosylation and the activity of nuclear factor κB (NF-κB). Human umbilical vein endothelial cells (HUVECs) were treated with 2 mM Hcy for 24 h. The cell lysates were treated using BST. (A and B) S-nitrosylated NF-κB was purified by affinity chromatography using streptavidin-agarose and analyzed by western blot analysis using an anti-p65 antibody. (C and D) Activity of NF-κB was detected by electrophoretic mobility shift assay (EMSA). The specificity of the bands was confirmed by supershifting with specific antibodies against p65 and p50 and by competition with specific cold competitor (100 x SPC) and non-specific cold competitor (100 x NSC) . The means ± SEM of three independent experiments are presented. vascular functions such as inflammation (6, 9) , apoptosis (8), permeability (20) , migration (21), cell growth (22) , and vascular stiffness (23) . Over 100 S-nitrosylation proteins have been identified in endothelial cells, many of which are important in regulating endothelial functions (24) . For example, S-nitrosylation can inhibit the activity of nicotinamide adenine dinucleotide, whereas it promotes the activity of thioredoxin-1, thus resulting in the prevention of oxidative stress in endothelial cells (5) . S-nitrosylation of p65 or p50 inhibits NF-κB activation, and suppresses inflammation in endothelial cells (9) . Hcy decreases the levels of NO and induces endothelial dysfunction (13) . In the present study, the levels of protein S-nitrosylation were reduced by Hcy in HUVECs, whereas the endogenous NO donor GSNO was able to rescue this reduction of protein S-nitrosylation. Thus, Hcy reduces the levels of protein S-nitrosylation by decreasing the levels of NO in endothelial cells. It was emphasized earlier that low Hcy does not evidently attenuate protein S-nitrosyaltion in a short period of time in vitro. However, when the concentration of Hcy was >0.5 mM, the degree of attenuation regarding S-nitrosylation protein was only marginally deepened. HHcy also decreased endothelium S-nitrosyaltion in a rat model. Although plasma Hcy concentration is low, chronic plasma Hcy stimulation on the endothelium over a long period of time may be a major cause.
Oxidative stress has been widely accepted as an important mechanism of Hcy-induced endothelial dysfunction and damage (25) . Hcy leads to the accumulation of ROS (26) . We found that Hcy significantly increased the levels of ROS, however, this effect was blocked by VitC and NAC.
In addition, VitC and NAC reversed the reduction of protein S-nitrosylation induced by Hcy, suggesting that Hcy reduces protein S-nitrosylation levels due to the excessive generation of ROS. We also observed that Hcy decreases the production of NO, which is consistent with previous studies (26) . Moreover, the reduction of NO is blocked by VitC. We hypothesized that Hcy reduces protein S-nitrosylation through the reduction of NO release which is induced by the overproduction of ROS. Under certain circumstances, ROS can also induce the dephosphorylation of Akt at Ser-473 (26), followed by Akt inactivation, leading to the dephosphorylation of eNOS at Ser-1177 and the reduction of NO generation in endothelial cells (27) . Hcy did not affect the expression levels of Akt and eNOS, but decreased the levels of phosphorylated Akt at Ser-473 and eNOS at Ser-1177 in endothelial cells (19) . We also found that Hcy may affect the phosphorylation of the Akt and eNOS proteins. Athough incubation with VitC increased the phosphorylation levels of Akt and eNOS proteins, the reduced levels of phosphorylation protein in Hcy-treated cells did not restore the control levels following incubation with VitC. This indicates that decreased phosphorylation levels of the Akt and eNOS proteins did not solely occur due to the accumulation of ROS. Furthermore, we found that the protein S-nitrosylation that was partially restored by VitC was abrogated by LY294002 and L-NAME in the endothelial cells treated with Hcy. Therefore, the protein S-nitrosylation inhibitory effect of Hcy may be associated with increased ROS levels together with a blockage of the Akt/ eNOS/NO pathway.
NF-κB is important in regulating endothelial pro-inflammatory genes, including VCAM-1 (28), while Hcy activates NF-κB via oxidative stress (29) . Accumulating evidence suggests that NF-κB activity is inhibited by S-nitrosylation. The p65 component of NF-κB is a target for S-nitrosylation, which inhibits its translocation into the cell nucleus (30) . The p50 subunit of NF-κB has also been reported to be S-nitrosylated, causing the inhibition of its binding to DNA (7, 9, 31) . In addition, inhibitory κB kinase, the catalytic subunit required for the activation of NF-κB, was S-nitrosylated, resulting in loss of its activity (32) . Thus, NO attenuated NF-κB activity through a diverse S-nitrosylation pathway. Hcy decreased the levels of cytoplasm S-nitrosylated p65, which may inhibit the translocation of NF-κB into the nucleus. GSNO rescued Hcy-induced decrease in levels of cytoplasm S-nitrosylated p65. Furthermore, Hcy enhanced the activity of NF-κB, suggesting that inhibition of S-nitrosylated p65 is one of numerous pathways that activate NF-κB following treatment with Hcy. Consequently, the protein expression of VCAM-1 was also enhanced.
In conclusion, findings of the present study demonstrate that Hcy attenuates protein S-nitrosylation in endothelial cells and rat aortas. This may be associated with increased levels of ROS and a blockage of the Akt/eNOS/NO pathway and promotion of inflammation. This finding provides new insight into HHcy-induced vascular damage. 
